NSCRI Cancer Hospital

What NSCRI Cancer Hospital does

NSCRI Cancer Hospital (legally Netaji Subhas Chandra Bose Cancer Hospital) is a 150-bed tertiary comprehensive cancer hospital based in Nayabad, Kolkata, India, operated by the not-for-profit Himadri Memorial Cancer Welfare Trust. Founded in 2004 by the late Dr. Ashis Mukhopadhyay — a Tata Memorial-trained hemato-oncologist who performed Eastern India's first bone marrow transplant — the hospital delivers end-to-end cancer care spanning medical, surgical, radiation, and nuclear oncology under one roof. It operates a Centre of Excellence for Peritoneal Cancers offering HIPEC and PIPAC (the first PIPAC in Eastern and North India), an Elekta Synergy linear accelerator enabling IMRT/IGRT/VMAT/SBRT/SGRT, a GE Discovery PET-CT scanner, a modern Bone Marrow Transplantation Unit inaugurated in January 2021, and an in-house molecular/liquid biopsy laboratory.

The hospital serves a catchment covering West Bengal, other Eastern Indian states, Bangladesh, Nepal, and Bhutan, with supplementary outreach clinics in Siliguri, Guwahati, and Malda and a district-level Cancer Service Coordinator referral network. Its GTM is sales-led: patients are acquired through direct visits, doctor referrals, community cancer detection camps, and the coordinator network. Revenue is generated primarily from inpatient and outpatient clinical services (IPD/OPD including chemotherapy, surgery, radiation, diagnostics, BMT, and pharmacy) at transparent subsidized pricing, with secondary revenue from paramedical diploma courses (affiliated with the State Medical Faculty of West Bengal) and an established clinical research unit that has completed approximately 65 global and national oncology trials sponsored by multinational pharmaceutical companies including Novartis, Pfizer, AstraZeneca, GSK, Sanofi, and Bristol-Myers Squibb. Notable clinical indicators include 6,000+ new patients per year, 30,000+ annual IPD admissions, 1,200+ annual radiation patients, and 400-500 major cancer surgeries per year.

Name

NSCRI Cancer Hospital

Legal name

Netaji Subhas Chandra Bose Cancer Hospital

Website

https://nscri.in

Company type

Private

Founded year

2004

Operating status

Operating

Headcount range

101–250 employees

Short description

NSCRI Cancer Hospital is a 150-bed, not-for-profit tertiary cancer hospital in Kolkata, India, providing end-to-end oncology care (medical, surgical, radiation, BMT, HIPEC/PIPAC) to patients across Eastern India, Bangladesh, and Nepal, with outreach clinics, clinical trials, and a Cancer Service Coordinator referral network.

Ownership category

akta.pro rank

Product category

Cancer Treatment Hospital / Oncology Services

NAICS

Specialty (except Psychiatric and Substance Abuse) Hospitals (622310), Diagnostic Imaging Centers (621512)

SIC

Services-Hospitals (8060)

akta.pro primary industry

Oncology & Cancer Specialty Hospitals (HLAFAHAC)

akta.pro secondary industries

Ambulatory Oncology Centers (Outpatient Chemo/Radiation) (HLAFABAI), Medical Oncology (HLAKAFAB), Gynecologic Oncology & Women’s Cancer Centers (HLAFAJAK), Head & Neck Surgery (ENT Oncology) (HLAKAMAF)

Keywords

• Cancer treatment services
• Medical oncology
• Radiation oncology
• Bone marrow transplantation
• Surgical oncology

Headquarters

HQ city

Kolkata

HQ country

India

HQ region

Asia

Offices4 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Supply Chain, Technology or R&D, Marketing or Sales

Revenue model

1. Patient Care Services: The hospital generates revenue through comprehensive inpatient (IPD) and outpatient (OPD) cancer care services including consultations, chemotherapy, surgery, radiation therapy, diagnostics, bone marrow transplantation, and pharmacy. Services are provided at transparent and affordable pricing with subsidized rates for underprivileged patients.
2. Paramedical Education: Affiliated with State Medical Faculty of West Bengal for conducting diploma courses in Medical Laboratory Technology, Radiotherapeutic Technology, Radiography, Critical Care Technology, and Operation Theater Technology. Generates revenue through course fees.
3. Clinical Trials: Conducts Phase I-IV clinical trials sponsored by national and multinational pharmaceutical companies (Novartis, GSK, Sanofi, Bristol-Myers, Pfizer, AstraZeneca, etc.). Revenue generated through trial execution fees.

Pricing tiers

Go-to-market motion1 record

Distribution channels5 records

Marketing channels7 records

Core offering

Netaji Subhas Chandra Bose Cancer Hospital (NSCRI) is a 150-bed tertiary comprehensive cancer hospital in Kolkata providing end-to-end cancer care from prevention to palliation. It integrates Medical Oncology, Surgical Oncology, Radiation Oncology, Nuclear Medicine, and Haematology under one roof, with a dedicated Bone Marrow Transplantation unit and a Centre of Excellence for Peritoneal Cancers offering HIPEC and PIPAC surgery. The hospital is operated by the Himadri Memorial Cancer Welfare Trust and serves patients from West Bengal, Eastern India, and neighbouring countries including Bangladesh.

Product overview

Netaji Subhas Chandra Bose Cancer Hospital (NSCRI) is a 150-bed tertiary comprehensive cancer hospital offering end-to-end cancer care from prevention to palliation. The hospital operates as an integrated cancer treatment center with multiple specialized departments including Medical Oncology/Chemotherapy, Surgical Oncology, Radiation Oncology, Nuclear Medicine, Haematology, and Bone Marrow Transplantation Unit. The facility provides advanced diagnostic services through Advanced Pathology, Molecular Laboratory, and Radiology departments, complemented by support services including 24-hour Pharmacy, Blood Bank, and Endoscopy Services. The hospital is recognized as a Centre of Excellence for Peritoneal Cancers and is the first centre to perform PIPAC surgery in Eastern and North India.

Differentiator

Problem solved

Functional benefit

Products and services

• Medical Oncology / Chemotherapy Systemic cancer treatment including chemotherapy, targeted therapies, hormonal therapy, immune therapies (monoclonal antibodies, check-point inhibitors), and haematopoietic bone marrow transplantation for adult and paediatric cancer patients.
• Surgical Oncology Cancer surgery services delivered through an integrated surgical suite comprising three general operation theatres, an operation theatre for brachytherapy delivery, and a state-of-the-art CSSD, including complex procedures for breast, colorectal, gynaecologic, head & neck, and GI cancers.
• Radiation Oncology High-precision radiation therapy using the Elekta Synergy linear accelerator enabling IMRT, IGRT, VMAT, SBRT, and Surface Guided Radiation Therapy (SGRT) treatments, with HDR Brachytherapy capabilities, for solid tumour patients.
• Nuclear Medicine Diagnostic and therapeutic nuclear medicine services including PET-CT scanning using a GE Discovery scanner, dual-head gamma camera imaging, and high-dose I-131 therapy for thyroid cancer.
• Haematology Diagnosis and treatment of blood disorders and blood cancers including leukaemia, lymphoma, myeloma, and thalassemia, with Bone Marrow Transplantation services for adult and paediatric patients.
• Pain & Palliative Care Specialised medical care focused on providing relief from the symptoms and stress of serious illness, addressing physical, psychological, social, and spiritual aspects of patient suffering for oncology patients.
• HIPEC & PIPAC Surgery Advanced surgical procedures for peritoneal surface malignancies, including Cytoreductive Surgery combined with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) and Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC), for ovarian, appendiceal, colorectal, and gastric cancers.
• One Stop Breast Clinic Comprehensive breast cancer assessment and diagnosis clinic providing rapid evaluation of breast symptoms such as lumps, pain, and skin changes, leading to expedited diagnostic workup and treatment planning.
• Advanced Pathology Pathology services including histopathology, cytology, tumour marker studies, FNACs, CT-guided trucut biopsies, and microbiology, delivered through automated analysers.
• Molecular Laboratory Molecular characterisation of solid cancers focusing on colon, rectum, pancreas, and ovarian cancers for biomarker identification, early diagnostics, treatment response assessment, and prognosis determination, including liquid biopsy for ctDNA and CTC analysis.
• Bone Marrow Transplantation Unit Stem cell and Bone Marrow Transplantation services including Autologous, Allogenic, and Haplotype Allogenic transplants for adult and paediatric patients with blood cancers and disorders.
• Interventional Radiology Minimally invasive, image-guided cancer procedures including biopsies and tumour reduction using radioactive particles, heat, cold, and electric current while minimising impact on surrounding healthy organs.
• Blood Bank Round-the-clock blood bank with component separation unit providing concentrated RBC, Fresh Frozen Plasma, Platelet concentrate, RDP, SDP, and plasma exchange therapies for cancer patients.
• 24-Hour Pharmacy Round-the-clock hospital pharmacy stocked with chemotherapeutic and advanced drugs for cancer patients, offering subsidised rates for IPD and OPD patients, especially those from underprivileged backgrounds.
• Endoscopy Services Diagnostic and therapeutic gastroenterology procedures including UGI endoscopy, colonoscopy, ERCP, stenting procedures (pyloroduodenal, oesophageal, colorectal), PEG, and endoscopic gastrojejunostomy for cancer patients.
• Anaesthesia & Critical Care Anaesthesia care, pain management, and life support including preoperative assessment, postoperative care in surgical ICU, and intensive care for critically ill cancer patients, including anaesthesia for advanced cancer surgery such as HIPEC and PIPAC.
• Radiology Full imaging cancer diagnostics including conventional and portable X-ray, ultrasonography, digital mammography, CT scan, MRI, and all types of image-guided biopsies.
• Paramedical Diploma Courses Affiliated diploma programmes for prospective allied-health students in Medical Laboratory Technology, Radiotherapeutic Technology, Radiography, Critical Care Technology, and Operation Theatre Technology, with placement support via the Cliniminds e-skilling partnership.
• Clinical Trials Service Execution of Phase I–IV oncology clinical trials for pharmaceutical sponsors across solid tumours (lung, breast, prostate, colon, head & neck, ovary) and haematological malignancies (lymphoma, chronic and acute leukaemias), under a CDSCO-registered Ethics Committee and GCP-compliant operations.

Quantifiable outcome

• 90% cure rate for cervical cancer detected at Stage 1 or 2A
• +5 more outcomes

Named customers7 records

Segments5 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Partnerships

Four partnerships are on record, tiered core and minor.

• ClinimindscoreStrategic or Co-development PartnerNCRI signed an MoU with Cliniminds to offer job-oriented e-skilling programmes certified by the Life Sciences Sector Skill Development Council, Ministry of Skill Development & Entrepreneurship. The agreement was signed between Kamal Shahani (Managing Director, Cliniminds) and Soma Mukhopadhyay (Managing Trustee, NCRI) in Kolkata. Cliniminds provides certification programmes that enhance employability in the healthcare and life sciences sector.
• Novartis, GSK, Sanofi, Bristol-Myers Squibb, Pfizer, AstraZeneca, Biocad, Hetero, Zidus Cadila, Lupin, DRL (and other pharmaceutical companies)coreOthersNCRI's Clinical Research and Clinical Trial Unit has conducted approximately 65 global and national clinical oncology trials sponsored by national and multinational pharmaceutical companies including Novartis, GSK, Sanofi Aventis, Bristol-Myers, Pfizer, Kariyopharm, Nicolas Piramal, J&J, Eli Lilly, AstraZeneca, Biocad, Hetero, Zidus Cadila, Lupin, and DRL. Trials cover solid tumours (lung, breast, prostate, colon, head & neck, ovary) and haematological malignancies (lymphoma, chronic and acute leukemias).
• Impact GuruminorOthersNCRI partners with Impact Guru, a crowdfunding platform, to help underprivileged patients raise funds for cancer treatment. Through this partnership, patients like Samarmita Pal (Acute Myeloid Leukemia) have been able to access life-saving treatment at NCRI.
• Association of Radiation Oncologists of India - West Bengal ChaptercoreStrategic or Co-development PartnerAcademic collaboration for the International ONCO Summit (NIOS) 2023 covering haematological, breast, and GI malignancies. Jointly organized academic event at Ozone Convention Centre, Kolkata.

Scale indicators13 records

Recent moves8 records

Expansion highlights6 records

Broad incumbents

• Max Institute of Cancer Care: Max Healthcare's dedicated cancer care programme offering medical, surgical, radiation oncology and BMT across North India - a broader hospital-group incumbent with overlapping oncology capabilities.
• Fortis Memorial Research Institute (FMRI): Large multi-specialty quaternary hospital in Gurugram with comprehensive oncology department - a broader incumbent offering overlapping radiation, medical and surgical oncology services.
• Apollo Cancer Centre: Apollo Hospitals' pan-India network of dedicated oncology centres (Chennai, Hyderabad, Kolkata, Delhi, etc.) offering medical, surgical and radiation oncology including BMT and clinical trials - a large incumbent with overlapping clinical offerings to NCRI's.

Direct peers

• Cancer Institute (WIA), Chennai: One of India's oldest dedicated cancer centres (est. 1954) offering comprehensive oncology services including BMT and clinical trials - a directly comparable specialty cancer hospital and academic research centre.
• Healthcare Global Enterprises (HCG): India's largest dedicated cancer-care chain with comprehensive oncology services including radiation, medical and surgical oncology plus BMT across multiple cities - a directly comparable specialty oncology operator with hub-and-spoke expansion strategy.
• Rajiv Gandhi Cancer Institute & Research Centre: Not-for-profit tertiary cancer hospital in Delhi offering medical, surgical and radiation oncology including BMT - a directly comparable charitable/societal cancer specialty hospital model with similar mission alignment to NCRI.
• Tata Medical Center, Kolkata: A 460-bed tertiary cancer hospital in New Town, Kolkata, operated by the Tata Trusts - the most prominent direct competitor to NCRI in Eastern India, offering the same comprehensive medical, surgical and radiation oncology under one roof plus BMT.
• Chittaranjan National Cancer Institute (CNCI): Government regional cancer centre in Kolkata providing comprehensive oncology services at subsidized rates - a directly comparable dedicated cancer centre serving overlapping patient populations in West Bengal.

Regional players

• Medica Superspecialty Hospital, Kolkata: Kolkata-based tertiary hospital providing cancer care including chemotherapy, radiation and surgery - a regional competitor sharing the same Eastern India catchment as NCRI.
• AMRI Hospitals, Kolkata: Kolkata-based multi-specialty hospital chain with dedicated oncology services and BMT unit - a regional multi-specialty player serving similar East Indian patient base as NCRI.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xtwitter.com/NCRI_Hospital
• Facebookfacebook.com/nscri.in
• LinkedInlinkedin.com/company/netaji-subhas-chandra-bose-cancer-hospital
• Instagraminstagram.com/ncrihospitalkolkata

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NSCRI Cancer Hospital